This review highlights the prognostic value and potential pathophysiological role of C-reactive protein across a wide spectrum of cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
May inform risk stratification across cardiovascular conditions; leaves open whether targeting CRP improves outcomes.
Clinicians involved in the care of patients with cardiovascular conditions have recently been confronted with an important body of literature linking inflammation and cardiovascular disease. Indeed, the level of systemic inflammation as measured by circulating levels of C-reactive protein (CRP) has been linked to prognosis in patients with atherosclerotic disease, congestive heart failure, atrial fibrillation, myocarditis, aortic valve disease and heart transplantation. In addition, a number of basic science reports suggest an active role for CRP in the pathophysiology of cardiovascular diseases. This article explores the potential role of CRP in disease initiation, progression, and clinical manifestations and reviews its role in the prediction of future events in clinical practice. Therapeutic interventions to decrease circulating levels of CRP are also reviewed.
No takes yet. Share an insight, caveat, or question.
Osman et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: